One child has been reported dead as cases of acute hepatitis of unknown origin have increased among children, the who said Wednesday. According to statistics, a total of 12 countries have reported at least 169 cases of children, of which 114 cases occurred in the UK. As of April 21, in addition to the UK, the countries reporting cases also include the United States, Spain, Israel, Denmark, Ireland, the Netherlands, Italy, Norway, France, Romania and Belgium.
The agency pointed out that China is the world’s heaviest burden of liver disease, with 90 million carriers of hepatitis B virus (HBV), 10 million carriers of hepatitis C virus (HCV), 7 million 1.7-3.1 patients with non-alcoholic liver disease and 7 million patients with cirrhosis. Given that liver disease has a large number of unmet treatment needs, the market space of innovative drugs is worth looking forward to. Many companies in the world and China have arranged this field. It is suggested to pay attention to the leading companies of innovative drugs for liver disease.
According to the theme database of financial Associated Press, among the relevant listed companies:
Fujian Cosunter Pharmaceutical Co.Ltd(300436) has been approved to be listed as nucleoside anti HBV products including Agam – adefovir dipivoxil, higan Ding lamivudine and en Gan Ding – ente Cave.
Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693) thymus Faxin for injection (“Kitai”) is an immune enhancing drug, which is mainly used for the treatment of various types of liver diseases, tumors, geriatrics and infectious diseases and the improvement of body immunity.
